Hostname: page-component-857557d7f7-nfgnx Total loading time: 0.001 Render date: 2025-12-12T06:47:02.251Z Has data issue: false hasContentIssue false
  • English
  • Français

A “Just Transition” for Drug-Resistant Tuberculosis

Part of: Antimicrobial Resistance: Just Transitions for Shared Futures

Published online by Cambridge University Press:  04 December 2025

Vijayashree Yellappa ,
Christopher Pell  and
Degu Jerene
Vijayashree Yellappa
Affiliation:
KNCV Tuberculosis Foundation, The Hague, The Netherlands
Christopher Pell*
Affiliation:
KNCV Tuberculosis Foundation, The Hague, The Netherlands Department of Global Health | Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands Amsterdam Public Health Research Institute, Global Health Program, Amsterdam, The Netherlands
Degu Jerene
Affiliation:
KNCV Tuberculosis Foundation, The Hague, The Netherlands
*
Corresponding author: Christopher Pell; Email: c.l.pell@amsterdamumc.nl
Rights & Permissions [Opens in a new window]

Abstract

Tuberculosis (TB) remains a serious health threat and strains of TB resistant to first-line therapies account for significant TB-related morbidity and mortality. Widely recognized as a disease of poverty concentrated in low- and middle-income countries, drug-resistant tuberculosis (DR-TB) is a result of deep-seated deprivation and the shortcomings of under-resourced health systems. Traditionally, the response to TB, and particularly DR-TB, has been focused on dealing with the infection and preventing onward transmission, for example, through isolating people with TB in sanatoria or specialized hospital wards. Recently, activists and policy makers have recognized the need to put people affected by the disease at the center of TB programs, but this is just the beginning of the necessary “just” transition from inequitable and unsustainable approaches to addressing TB to ones that are inclusive, community-centered, and resilient. In this article, we examine antimicrobial resistance in TB and highlight the need for a multisectoral, justice-oriented approach that goes beyond biomedical paradigms—we propose a “just” transition that addresses the unequal burden of human suffering and injustices that have become systemic in TB programs. We see a “just transition” as involving long-term structural changes to technologies, policy, infrastructure, scientific knowledge, and practice.

Keywords

antimicrobial resistancedrug resistanceinequityjusticetuberculosis

Information

Type
Article
Information
Public Humanities , Volume 1 , 2025 , e177
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NC
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial licence (http://creativecommons.org/licenses/by-nc/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
Copyright
© The Author(s), 2025. Published by Cambridge University Press

1. Framing the need for a "just transition" for drug-resistant tuberculosis

Tuberculosis (TB) remains a serious global health threat, and strains resistant to first-line therapies account for an important share of TB-related illness and death.Footnote 1 Already known as a disease of poverty concentrated in low- and middle-income countries (LMICs), drug-resistant tuberculosis (DR-TB) highlights not only deep-seated deprivation but also the shortcomings of under-resourced health systems.Footnote 2

Traditionally, the response to TB, and particularly DR-TB, has been focused on dealing with the infection and preventing onward transmission, for example, through isolating people with TB in sanatoria or specialized hospital wards. The needs (and preferences) of people with TB disease were hence considered subordinate to the public health imperative of preventing onward transmission.Footnote 3 Recently, activists and policy makers have recognized the need to put people at the center of the approach to TB, but this is just the beginning of the necessary “just” transition from inequitable and unsustainable approaches to addressing TB towards ones that are inclusive, community-centered, and resilient.Footnote 4

In this article, we examine antimicrobial resistance (AMR) in TB. We focus on DR-TB because of the particular need for a multisectoral, justice-oriented approach that goes beyond biomedical paradigms—we propose this as a “just” transition that addresses the unequal burden of human suffering in its fullness and seeks to address injustices that have become systemic in TB programs.Footnote 5 The injustices include the uneven distribution of diagnostic capacity, the lack of investment in and availability of effective and tolerable treatment, and the exclusion of people affected by TB from shaping program priorities.Footnote 6 These programmatic inequities lead to delayed treatment initiation, particularly in rural areas, worse treatment outcomes, and deepened marginalization among already vulnerable populations. In discussing this transition, we draw from scholarship around equity considerations in response to the climate crisis and see a “just transition” as involving long-term structural changes to technologies, policy, infrastructure, scientific knowledge, and practice.Footnote 7

2. Poverty and drug-resistant TB

Globally, the burden of TB is concentrated in LMICs.Footnote 8 Furthermore, the poorest in societies are also at greatest risk of developing the disease.Footnote 9 Overcrowded housing and malnutrition are key drivers of TB, its transmission and the development of active disease.Footnote 10 The risk of TB is also particularly high among people living with HIV, another infection that is entwined with global and local inequities.Footnote 11 And with multiple episodes of TB, the risk of DR-TB increases.Footnote 12

Poverty compounds the impacts of an episode of TB, whilst TB also has economic impacts for individuals and families. The poorest in society often struggle to deal with the economic burden of accessing TB care and following the treatment regimens, which—because of direct travel and treatment costs as well as indirect opportunity costs—can exceed 50% of annual household income.Footnote 13 Moreover, an episode of TB often leaves long-term sequelae, which are poorly understood and can be life-limiting.Footnote 14 Moreover, long-term sequelae of TB often require extended rehabilitation, which entails long-term healthcare expenditures and compounds financial hardship.Footnote 15

These impacts are particularly pronounced in the case of DR-TB.Footnote 16 The treatment regimens are longer (lasting from 6 to 20 months) and their toxicity profiles—although much improved over recent years—can have long-term health impacts.Footnote 17 Treatment regimens for DR-TB vary according to the specific resistance profiles (and sometimes limited drug susceptibility testing), but they are often less tolerable and more complex than those for drug-susceptible TB. Treatment can also involve switching between regimens, which prolongs the course. With the higher drug toxicity and increased pill burden, people with DR-TB often face adherence challenges and treatment success rates remain lower than for drug-susceptible TB, often below 60% in high-burden settings.Footnote 18 Treatment regimens for DR-TB carry substantial risks of adverse effects, including peripheral neuropathy from linezolid and hepatotoxicity from other agents, further complicating adherence.Footnote 19

For those affected by TB, the consequences are not only health-related; rather they often also face catastrophic health expenditures and loss of livelihood. For example, in Zimbabwe, DR-TB–affected households experienced a median loss of 67% of annual income due to treatment costs, travel expenses, and lost wages.Footnote 20 These long-term livelihood impacts can drag families into a spiral of poverty and food insecurity that further increases their risk of TB.Footnote 21 There are psycho-social consequences, with people affected by TB unable to fulfill their social (or economic) roles and experiencing social isolation and othering because of TB-related stigma.Footnote 22

3. Inequities in approaches to addressing TB

The challenges of addressing DR-TB mirror those of AMR more broadly. Key issues across LMICs include insufficient laboratory capacity, inadequate drug development supply chains, and under-resourced primary health facilities.Footnote 23 These problems contribute to delayed diagnoses, suboptimal treatment, and persistent transmission, which promote the emergence and spread of resistance traits.Footnote 24 In DR-TB, this is particularly pronounced because of the difficulties of identifying resistance, the complex treatment regimens, and the interactions with HIV infection.Footnote 25

In LMICs, diagnostic and laboratory infrastructure for DR-TB is often inadequate, particularly in primary care facilities and communities.Footnote 26 Identifying resistance in TB still often relies on culture-based laboratory processes, which take weeks. Even though more rapid molecular sequencing approaches have been developed, the lack of resources and infrastructure prevents their implementation in many LMICs.Footnote 27 Hence, receiving a diagnosis can involve repeated long-distance travel to reach diagnostic centers and multiple provider consultations. This means prolonged work absenteeism, income loss, direct expenses for tests not covered by public health programs, and social stigma that exacerbates emotional distress.Footnote 28

The challenges of treating DR-TB are particularly pronounced because—in spite of recent improvements—regimens are often long, toxic, and difficult to access. Positive developments include the recently recommended all-oral regimens that contain bedaquiline, pretomanid, and linezolid (BPaL), although they still require at least 6 months of treatment.Footnote 29 However, bedaquiline was the first new drug specifically developed for TB in more than 40 years, and although it represents a major therapeutic advance, it is the result of an antibiotic pipeline with few future candidate compounds.

Global access to bedaquiline also remains uneven—regulatory approval is incomplete in several high-burden countries, and treatment costs can be prohibitive for uninsured patients.Footnote 30 Donation programs, such as the Janssen bedaquiline initiative, have provided some relief but have been insufficient to meet demand sustainably.Footnote 31 Hence, inadequate health systems mean that even when effective tools exist, they do not reliably reach those who need them most. The poorest often face the double burden of failing health systems and burdensome treatment regimens. Highlighting the moral imperative to accelerate research and delivery of shorter and more tolerable (DR-)TB regimens.Footnote 32

4. A necessary “just transition”

Addressing DR-TB as part of broader AMR stewardship requires transformation along the care trajectory, from screening and diagnosis to treatment. Equitable access to rapid, reliable diagnostics and strengthening laboratory systems for early detection and tailored treatment is essential. Integrating AMR management into TB diagnostic platforms, especially at peripheral health facilities, can enhance efficiency and improve patient outcomes.Footnote 33 Investment in new treatments is also essential to identify less toxic and shorter regimens for DR-TB. These are approaches that reflect interventions deeply rooted in biomedical models that prioritize pathogen-specific interventions, drug development, and clinical protocols. Although indispensable, they are insufficient when decoupled from broader health system strengthening.Footnote 34 Alone, they also neglect the recent shift in TB programming and care toward a more person-centered approach.Footnote 35

Person-centered care is characterized as holistic, individualized, respectful, and empowering, with the person (with TB) central to the process of care through informed, shared decision-making and self-determination.Footnote 36 In person-centered care, the person affected by TB and healthcare providers engage in collaborative decision-making, discussing options, treatment risks, and benefits.Footnote 37 In this approach, the person affected by TB is an active participant, rather than a passive recipient of care.Footnote 38

Although the shift to person-centered care is essential, it is only the start of a transition needed to address DR-TB in an effective and fair manner. In considering what is needed, we draw from the concept of a just transition—a socio-technical transition, which involves deep structural changes in systems, and entails long-term and complex changes to technologies, policies, infrastructure, scientific knowledge, and social and cultural practices.Footnote 39 This “just” transition requires moving beyond a narrow biomedical approach to one that integrates social, economic, and systemic determinants of health.Footnote 40 These investments must be planned and financed as part of broader health system reforms, ensuring they serve multiple health needs.

A “just transition” for TB means confronting the structural forces that seed vulnerability in the first place. Although new drugs, diagnostics, and vaccines are essential, their impact will be compromised unless they are paired with policies that address crowded housing, insecure work, malnutrition, weak labor protections, and the marginalization of affected communities. A truly just transition therefore reframes TB control as a question of distributive justice and democratic accountability: reallocating resources toward social protection schemes, strengthening primary health services, guaranteeing living wages, and empowering communities to shape research priorities and service delivery.Footnote 41 In other words, it shifts the center of gravity from laboratories and hospitals to the everyday environments where risk is produced—and where equitable social and economic reforms can dismantle the very conditions that allow drug-resistant strains to flourish.

Reframing the approach to DR-TB through the lens of “just transitions” invites us to imagine a different future: one in which science and solidarity go hand in hand; in which innovation is directed by the concept of health equity; in which communities are empowered and viewed as equal partners, not passive recipients and in which the right to health is realized universally.

5. Engendering the transition

This future will not emerge spontaneously; it requires deliberate choices, courageous leadership, and sustained advocacy. By embracing the principles of justice, inclusivity, and systemic transformation, we can build a shared future that is not only more resistant to the threats of TB and AMR but also more aligned with the values of human dignity and collective well-being. Declarations from recent high-level United Nations meetings on TB have incorporated human rights commitments, including the right to health, to ending stigma and discrimination against people affected by TB, and promoting access to affordable treatments.Footnote 42 Countries have, however, often not met these commitments.Footnote 43 Furthermore, although the WHO’s End TB Strategy and most national AMR action plans recognize equity in principle, they rarely embed enforceable measures that channel resources to the communities carrying the heaviest burden of resistance.

Individuals living in vulnerable situations often lack the opportunity and agency to voice their needs and ideas. Effective TB responses must be grounded in the realities of affected communities.Footnote 44 Communities can be key agents in TB elimination when appropriately supported, for example, India’s TB Mukt Panchayat initiative and community health worker programs in South Africa, which improved case detection and treatment adherence.Footnote 45 Community engagement is not an optional add-on but a foundational element of a just transition.Footnote 46 People-centered approaches, including the involvement of TB survivors, grassroots health workers, and civil society organizations, have demonstrated impact in improving case detection, reducing stigma, and supporting treatment adherence.Footnote 47 However, in many settings, community-based responses are underfunded, under-researched, and inadequately integrated into national health strategies. A just transition means rebalancing these inequities and investing in the leadership, capacities, and innovations of communities themselves. Communities are key agents in TB elimination efforts, offering culturally grounded, trusted interventions that complement formal health systems.Footnote 48

Research agendas must also reflect the lived realities of patients and the systemic barriers they face. Innovation must not only produce new tools but also address affordability, accessibility, and usability in real-world settings.Footnote 49 A just transition envisions research driven by public health needs rather than commercial priorities, supported by financing mechanisms that prioritize equitable access. At the same time, the ethics of innovation must be scrutinized.Footnote 50 Who sets the agenda? Who benefits? Who is left behind? These questions are particularly relevant in the context of TB, for which global North–South power imbalances continue to influence funding, policy, and access to tools.

Author contribution

Conceptualization: D.J., V.Y., C.P.

Conflicts of interest

The authors declare none.

Footnotes

1 Chin et al. Reference Chin, Anibarro, Chang, Palasuberniam, Mustapha, Sarmiento and Acosta2024; World Health Organization 2024.

2 Cox et al. Reference Cox, Cox, Pai, Stillo, Citro and Brigden2019.

3 Cox et al. Reference Cox, Cox, Pai, Stillo, Citro and Brigden2019; Farhat et al. Reference Farhat, Cox, Ghanem, Denkinger, Rodrigues, Abd El Aziz and Enkh-Amgalan2024.

4 Horter et al. Reference Horter, Daftary, Keam, Bernays, Bhanushali, Chavan and Denholm2021; Odone et al. Reference Odone, Roberts, Dara, van den Boom, Kluge and McKee2018; Reid et al. Reference Reid, Arinaminpathy, Bloom, Bloom, Boehme, Chaisson and Chin2019.

5 Bhargava, Bhargava, and Pai Reference Bhargava, Bhargava and Pai2024.

6 Chatterjee et al. Reference Chatterjee, Das, Stallworthy, Bhambure, Munje and Vassall2024; Giovenco et al. Reference Giovenco, Shah, Ansorge, Operario and Gandhi2025.

7 Wang and Lo Reference Wang and Lo2021.

8 World Health Organization 2024.

9 Xue et al. Reference Xue, Zhou, Wang, Lan, Lian, Fan and Xu2022.

10 Lee et al. Reference Lee, Kwon, Go and Cho2022; Sinha et al. Reference Sinha, Davis, Saag, Wanke, Salgame, Mesick, Horsburgh and Hochberg2019.

11 Aaron et al. Reference Aaron, Saadoun, Calatroni, Launay, Memain, Vincent and Marchal2004.

12 Lukoye et al. Reference Lukoye, Ssengooba, Musisi, Kasule, Cobelens, Joloba and Gomez2015.

13 Foster et al. Reference Foster, Vassall, Cleary, Cunnama, Churchyard and Sinanovic2015.

14 Chatterjee et al. Reference Chatterjee, Das, Stallworthy, Bhambure, Munje and Vassall2024; Nightingale et al. Reference Nightingale, Carlin, Meghji, McMullen, Evans, van der Zalm and Anthony2023.

15 Nightingale et al. Reference Nightingale, Carlin, Meghji, McMullen, Evans, van der Zalm and Anthony2023.

16 Akalu et al. Reference Akalu, Clements, Wolde and Alene2023.

17 Farhat et al. Reference Farhat, Cox, Ghanem, Denkinger, Rodrigues, Abd El Aziz and Enkh-Amgalan2024.

18 World Health Organization 2024.

19 Farhat et al. Reference Farhat, Cox, Ghanem, Denkinger, Rodrigues, Abd El Aziz and Enkh-Amgalan2024.

20 Timire et al. Reference Timire, Houben, Pedrazzoli, Ferrand, Calderwood, Bond, Mbiba and Kranzer2024.

21 Balinda, Sugrue, and Ivers Reference Balinda, Sugrue and Ivers2019.

22 Adejumo et al. Reference Adejumo, Jinabhai, Daniel and Haffejee2025; Redwood et al. Reference Redwood, Fox, Nguyen, Bernarys, Mason, Vu, Nguyen and Mitchell2022.

23 Cox et al. Reference Cox, Cox, Pai, Stillo, Citro and Brigden2019.

24 Cipriano et al. Reference Cipriano, Chau, Jashi, Kickbusch, Koonin, Mofokeng and Phumaphi2024.

25 Oga-Omenka et al. Reference Oga-Omenka, Boffa, Kuye, Dakum, Menzies and Zarowsky2020.

26 Otchere et al. Reference Otchere, Asante-Poku, Akpadja, Diallo, Sanou, Asare and Osei-Wusu2024.

27 Farhat et al. Reference Farhat, Cox, Ghanem, Denkinger, Rodrigues, Abd El Aziz and Enkh-Amgalan2024.

28 Redwood et al. Reference Redwood, Fox, Nguyen, Bernarys, Mason, Vu, Nguyen and Mitchell2022; Yellappa et al. Reference Yellappa, Lefèvre, Battaglioli, Devadasan and Van der Stuyft2017.

29 Gopalaswamy et al. Reference Gopalaswamy, Aravindhan, Narayanan and Subbian2024.

30 Ravinetto et al. Reference Ravinetto, Henriquez, Srinivas, Bradley, Coetzee, Ochoa and Ngabonziza2024.

31 Ravinetto et al. Reference Ravinetto, Henriquez, Srinivas, Bradley, Coetzee, Ochoa and Ngabonziza2024.

32 Giovenco et al. Reference Giovenco, Shah, Ansorge, Operario and Gandhi2025.

33 Hasan et al. Reference Hasan, Shakoor, Hanefeld and Khan2018.

34 Bhargava, Bhargava, and Pai Reference Bhargava, Bhargava and Pai2024.

35 Horter et al. Reference Horter, Daftary, Keam, Bernays, Bhanushali, Chavan and Denholm2021.

36 Reid et al. Reference Reid, Arinaminpathy, Bloom, Bloom, Boehme, Chaisson and Chin2019.

37 Horter et al. Reference Horter, Daftary, Keam, Bernays, Bhanushali, Chavan and Denholm2021.

38 Horter et al. Reference Horter, Daftary, Keam, Bernays, Bhanushali, Chavan and Denholm2021; Reid et al. Reference Reid, Arinaminpathy, Bloom, Bloom, Boehme, Chaisson and Chin2019.

39 Wang and Lo Reference Wang and Lo2021.

40 Bhargava, Bhargava, and Pai Reference Bhargava, Bhargava and Pai2024.

41 Engel et al. Reference Engel, Apolosi, Bhargava, Bhan, Celan, Mak and Chikovore2024.

42 United Nations 2023.

43 Citro Reference Citro2024.

44 Ashesh et al. Reference Ashesh, Mehra, Madan and Furin2025.

45 Njarekkattuvalappil et al. Reference Njarekkattuvalappil, Shewade, Sharma, Suseela and Sharma2024; Venkatesan et al. Reference Venkatesan, Faust, Lobo, Enkh-Amgalan, Kunor, Sifumba and Rane2025.

46 Topaloglou et al. Reference Topaloglou, Kouskoura, Janikowska, Grozeva, Nikolaidou, Karagiannis and Kulczycka2024.

47 Tiangco et al. Reference Tiangco, Mier, Mier-Alpaño, Muego, Tongson and del Pilar-Labarda2025; Venkatesan et al. Reference Venkatesan, Faust, Lobo, Enkh-Amgalan, Kunor, Sifumba and Rane2025.

48 Njarekkattuvalappil et al. Reference Njarekkattuvalappil, Shewade, Sharma, Suseela and Sharma2024.

49 Engel et al. Reference Engel, Apolosi, Bhargava, Bhan, Celan, Mak and Chikovore2024.

50 Komparic et al. Reference Komparic, Dawson, Boulanger, Upshur and Silva2019.

References

Aaron, L., Saadoun, D., Calatroni, I., Launay, O., Memain, N., Vincent, V., Marchal, G., et al. 2004. “Tuberculosis in HIV-Infected Patients: A Comprehensive Review.” Clinical Microbiology and Infection 10 (5): 388–98. https://doi.org/10.1111/j.1469-0691.2004.00758.x.CrossRefGoogle ScholarPubMed
Adejumo, Olusola Adedeji, Jinabhai, Champaklal, Daniel, Olusoji, and Haffejee, Firoza. 2025. “The Effects of Stigma and Social Support on the Health-Related Quality of Life of People with Drug Resistance Tuberculosis in Lagos, Nigeria.” Quality of Life Research 34 (5): 1305–16. https://doi.org/10.1007/s11136-025-03902-5.CrossRefGoogle ScholarPubMed
Akalu, T.Y., Clements, A.C.A., Wolde, H.F., and Alene, K.A.. 2023. “Economic Burden of Multidrug-Resistant Tuberculosis on Patients and Households: a Global Systematic Review and Meta-Analysis.” Scientific Reports 13 (1): 22361. https://doi.org/10.1038/s41598-023-47094-9.CrossRefGoogle ScholarPubMed
Ashesh, A., Mehra, C., Madan, V., and Furin, J.. 2025. “Reimagining Community Engagement in TB Elimination: A Perspective from the Field.” IJTLD Open 2 (1): 3–5. https://doi.org/10.5588/ijtldopen.24.0578.CrossRefGoogle ScholarPubMed
Balinda, Ingabire G., Sugrue, Diarmuid D., and Ivers, Louise C.. 2019. “More than Malnutrition: A Review of the Relationship between Food Insecurity and Tuberculosis.” Open Forum Infectious Diseases 6 (4): ofz102. https://doi.org/10.1093/ofid/ofz102.CrossRefGoogle ScholarPubMed
Bhargava, Anurag, Bhargava, Madhavi, and Pai, Madhukar. 2024. “Tuberculosis: A Biosocial Problem that Requires Biosocial Solutions.” Lancet 403 (10443): 2467–9. https://doi.org/10.1016/S0140-6736(24)00489-6.CrossRefGoogle ScholarPubMed
Chatterjee, Susmita, Das, Palash, Stallworthy, Gayatri, Bhambure, Gayatri, Munje, Radha, and Vassall, Anna. 2024. “Catastrophic Costs for Tuberculosis Patients in India: Impact of Methodological Choices.” PLOS Global Public Health 4 (4): e0003078. https://doi.org/10.1371/journal.pgph.0003078.CrossRefGoogle ScholarPubMed
Chin, Kai Ling, Anibarro, Luis, Chang, Zi Yuan, Palasuberniam, Praneetha, Mustapha, Zainal Arifin, Sarmiento, Maria E., and Acosta, Armando. 2024. “Impacts of MDR/XDR-TB on the Global Tuberculosis Epidemic: Challenges and Opportunities.” Current Research in Microbial Sciences 7: 100295. https://doi.org/10.1016/j.crmicr.2024.100295.CrossRefGoogle ScholarPubMed
Cipriano, Pamela, Chau, James, Jashi, Mariam, Kickbusch, Ilona, Koonin, Justin, Mofokeng, Tlaleng, Phumaphi, Joy, et al. 2024. “Leveraging Universal Health Coverage to Leave no One behind in Tackling AMR.” The Lancet Global Health 12 (9): e1389–90. https://doi.org/10.1016/S2214-109X(24)00309-7.CrossRefGoogle ScholarPubMed
Citro, Brian. 2024. “Activating Law and Human Rights to End Tuberculosis: An Empirical Assessment of Ten Countries’ Fulfillment of United Nations Commitments.” India Health Law Review 21 (1): 2–60.Google Scholar
Cox, V., Cox, H., Pai, M., Stillo, J., Citro, B., and Brigden, G.. 2019. “Health Care Gaps in the Global Burden of Drug-Resistant Tuberculosis.” The International Journal of Tuberculosis and Lung Disease 23 (2): 125–35. https://doi.org/10.5588/ijtld.18.0866.CrossRefGoogle ScholarPubMed
Engel, N., Apolosi, I., Bhargava, A., Bhan, A., Celan, C., Mak, A., Chikovore, J., et al. 2024. “Building Social Equity and Person-Centred Innovation into the End TB Response.” The International Journal of Tuberculosis and Lung Disease 28 (11): 517–20. https://doi.org/10.5588/ijtld.24.0338.CrossRefGoogle ScholarPubMed
Farhat, Maha, Cox, Helen, Ghanem, Marwan, Denkinger, Claudia M., Rodrigues, Camilla, Abd El Aziz, Mirna S., Enkh-Amgalan, Handaa, et al. 2024. “Drug-Resistant Tuberculosis: a Persistent Global Health Concern.” Nature Reviews. Microbiology 22 (10): 617–35. https://doi.org/10.1038/s41579-024-01025-1.CrossRefGoogle ScholarPubMed
Foster, Nicola, Vassall, Anna, Cleary, Susan, Cunnama, Lucy, Churchyard, Gavin, and Sinanovic, Edina. 2015. “The Economic Burden of TB Diagnosis and Treatment in South Africa.” Social Science & Medicine 130: 42–50. https://doi.org/10.1016/j.socscimed.2015.01.046.CrossRefGoogle ScholarPubMed
Giovenco, D., Shah, N.S., Ansorge, K., Operario, D., and Gandhi, N.R.. 2025. “New Drugs Are Not Enough: addressing Social Determinants as a Critical Component of Drug-Resistant TB Care.” IJTLD Open 2 (4): 183–6. https://doi.org/10.5588/ijtldopen.25.0075.CrossRefGoogle ScholarPubMed
Gopalaswamy, Radha, Aravindhan, Vivekanandhan, Narayanan, Shridhar, and Subbian, Selvakumar. 2024. “Editorial: Newer Initiatives in Detection, Drug Discovery and Therapeutic Management of Drug-Resistant Tuberculosis.” Frontiers in Tropical Diseases 5: 1528428. https://doi.org/10.3389/fitd.2024.1528428.CrossRefGoogle Scholar
Hasan, Rumina, Shakoor, Sadia, Hanefeld, Johanna, and Khan, Mishal. 2018. “Integrating Tuberculosis and Antimicrobial Resistance Control Programmes.” Bulletin of the World Health Organization 96 (3): 194–200. https://doi.org/10.2471/BLT.17.198614.CrossRefGoogle ScholarPubMed
Horter, S., Daftary, A., Keam, T., Bernays, S., Bhanushali, K., Chavan, D., Denholm, J., et al. 2021. “Person-Centred Care in TB.” The International Journal of Tuberculosis and Lung Disease 25 (10): 784–7. https://doi.org/10.5588/ijtld.21.0327.CrossRefGoogle ScholarPubMed
Komparic, Ana, Dawson, Angus, Boulanger, Renaud F., Upshur, Ross E. G., and Silva, Diego S.. 2019. “A Failure in Solidarity: Ethical Challenges in the Development and Implementation of New Tuberculosis Technologies.” Bioethics 33 (5): 557–67. https://doi.org/10.1111/bioe.12554.CrossRefGoogle ScholarPubMed
Lee, Ju‑Yeun, Kwon, Namhee, Go, Ga‑yeon, and Cho, Sung‑il. 2022. “Inadequate Housing and Pulmonary Tuberculosis: a Systematic Review.” BMC Public Health 22 (1): 622. https://doi.org/10.1186/s12889-022-12879-6.CrossRefGoogle ScholarPubMed
Lukoye, Deus, Ssengooba, Willy, Musisi, Kenneth, Kasule, George W., Cobelens, Frank G. J., Joloba, Moses, and Gomez, Gabriela B.. 2015. “Variation and Risk Factors of Drug Resistant Tuberculosis in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.” BMC Public Health 15: 291. https://doi.org/10.1186/s12889-015-1614-8.CrossRefGoogle ScholarPubMed
Nightingale, R., Carlin, F., Meghji, J., McMullen, K., Evans, D., van der Zalm, M.M., Anthony, M.G., et al. 2023. “Post-TB Health and Wellbeing.” The International Journal of Tuberculosis and Lung Disease 27 (4): 248–83. https://doi.org/10.5588/ijtld.22.0514.CrossRefGoogle ScholarPubMed
Njarekkattuvalappil, Swathi Krishna, Shewade, Hemant Deepak, Sharma, Parth, Suseela, Rakesh Purushothama Bhat, and Sharma, Nandini. 2024. “How Can TB Mukt Panchayat Initiative Contribute towards Ending Tuberculosis in India?” The Lancet Regional Health. Southeast Asia 24: 100376. https://doi.org/10.1016/j.lansea.2024.100376.CrossRefGoogle Scholar
Odone, A., Roberts, B., Dara, M., van den Boom, M., Kluge, H., and McKee, M.. 2018. “People- and Patient-Centred Care for Tuberculosis: Models of Care for Tuberculosis.” The International Journal of Tuberculosis and Lung Disease 22 (2): 133–8. https://doi.org/10.5588/ijtld.17.0608.CrossRefGoogle ScholarPubMed
Oga-Omenka, Charity, Boffa, Jody, Kuye, Joseph, Dakum, Patrick, Menzies, Dick, and Zarowsky, Christina. 2020. “Understanding the Gaps in DR-TB Care Cascade in Nigeria: A Sequential Mixed-Method Study.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 21: 100193. https://doi.org/10.1016/j.jctube.2020.100193.CrossRefGoogle ScholarPubMed
Otchere, Isaac, Asante-Poku, Adwoa, Akpadja, Kodjo Francis, Diallo, Awa Ba, Sanou, Adama, Asare, Prince, Osei-Wusu, Stephen et al. 2024. “Opinion Review of Drug Resistant Tuberculosis in West Africa: tackling the Challenges for Effective Control.” Frontiers in Public Health 12: 1374703. https://doi.org/10.3389/fpubh.2024.1374703.CrossRefGoogle ScholarPubMed
Ravinetto, Raffaella, Henriquez, Rodrigo, Srinivas, Prashant N, Bradley, Hazel, Coetzee, Renier, Ochoa, Theresa J, Ngabonziza, Jean Claude Semuto et al. 2024. “Shaping the Future of Global Access to Safe, Effective, Appropriate and Quality Health Products.” BMJ Global Health 9 (1): e014425. https://doi.org/10.1136/bmjgh-2023-014425.CrossRefGoogle ScholarPubMed
Redwood, Lisa, Fox, Greg J., Nguyen, Thu Anh, Bernarys, Sarah, Mason, Paul, Vu, Van Anh, Nguyen, Viet Nhung, and Mitchell, Ellen M. H.. 2022. “Good Citizens, Perfect Patients, and Family Reputation: Stigma and Prolonged Isolation in People with Drug-Resistant Tuberculosis in Vietnam.” PLOS Global Public Health 2 (6): e0000681. https://doi.org/10.1371/journal.pgph.0000681.CrossRefGoogle ScholarPubMed
Reid, Michael, Arinaminpathy, Nimalan, Bloom, Amy, Bloom, Barry R., Boehme, Catharina, Chaisson, Richard, Chin, Daniel P. et al. 2019. “Building a Tuberculosis-Free World: The Lancet Commission on Tuberculosis.” Lancet 393 (10178): 1331–84. https://doi.org/10.1016/S0140-6736(19)30024-8.CrossRefGoogle ScholarPubMed
Sinha, Sinha, Davis, Juliana, Saag, Lauren, Wanke, Christine, Salgame, Padmini, Mesick, Jackson, Horsburgh, C. Robert, and Hochberg, Natasha S.. 2019. “Undernutrition and Tuberculosis: Public Health Implications.” The Journal of Infectious Diseases 219 (9): 1356–63. https://doi.org/10.1093/infdis/jiy675.CrossRefGoogle ScholarPubMed
Tiangco, Pauline Marie Padilla, Mier, Abigail Ruth, Mier-Alpaño, Jana Deborah, Muego, Paul, Tongson, Excelsa, and del Pilar-Labarda, Meredith. 2025. “Community Participation in Social Innovations in Health: a Qualitative Study of Women’s Engagement in a Local Tuberculosis Clinic in the Philippines.” BMJ Innovations 11 (1): 22–7. https://doi.org/10.1136/bmjinnov-2024-001279.CrossRefGoogle Scholar
Timire, Collins, Houben, Rein M. G. J., Pedrazzoli, Debora, Ferrand, Rashida A., Calderwood, Claire J., Bond, Virginia, Mbiba, Fredrick, and Kranzer, Katharina. 2024. “Higher Loss of Livelihood and Impoverishment in Households Affected by Tuberculosis Compared to Non-Tuberculosis Affected Households in Zimbabwe: A Cross-Sectional Study.” PLOS Global Public Health 4 (6): e0002745. https://doi.org/10.1371/journal.pgph.0002745.CrossRefGoogle ScholarPubMed
Topaloglou, Lefteris, Kouskoura, Amalia, Janikowska, Olga, Grozeva, Rumyana, Nikolaidou, Konstantinia, Karagiannis, Ioannis, and Kulczycka, Joanna. 2024. “The Interplay between Just Energy Transition and Community Engagement: Assessing Collaborative Pathways in Greece, Poland and Bulgaria.” Energy Research & Social Science 116: 103708. https://doi.org/10.1016/j.erss.2024.103708.CrossRefGoogle Scholar
United Nations. 2023. UN General Assembly High-Level Meeting on the Fight against Tuberculosis. Political Declaration. United Nations.Google Scholar
Venkatesan, N., Faust, L., Lobo, R., Enkh-Amgalan, H., Kunor, T., Sifumba, Z., Rane, S., et al. 2025. “Fighting Tuberculosis Hand in Hand: A Call to Engage Communities Affected by TB as Essential Partners in Research.” PLOS Glob Public Health 5 (4): e0004437. https://doi.org/10.1371/journal.pgph.0004437.CrossRefGoogle Scholar
Wang, Xinxin, and Lo, Kevin. 2021. “Just Transition: A Conceptual Review.” Energy Research & Social Science 82: 102291. https://doi.org/10.1016/j.erss.2021.102291.CrossRefGoogle Scholar
World Health Organization. 2024. World Tuberculosis Report 2024. World Health Organization.Google Scholar
Xue, Yi, Zhou, Jie, Wang, Peng, Lan, Jun-hong, Lian, Wen-qin, Fan, Yue-Ying, Xu, Bei-Ni et al. 2022. “Burden of Tuberculosis and its Association with Socio-Economic Development Status in 204 Countries and Territories, 1990-2019.” Frontiers in Medicine 9: 905245. https://doi.org/10.3389/fmed.2022.905245.CrossRefGoogle ScholarPubMed
Yellappa, Vijayashree, Lefèvre, Pierre, Battaglioli, Tullia, Devadasan, Narayanan, and Van der Stuyft, Patrick. 2017. “Patients Pathways to Tuberculosis Diagnosis and Treatment in a Fragmented Health System: A Qualitative Study from a South Indian District.” BMC Public Health 17 (1): 635. https://doi.org/10.1186/s12889-017-4627-7.CrossRefGoogle Scholar